Name | Dimesna |
Synonyms | Dimesna 16208-51-8 Mesna EP Impurity D DIMESNA(SUBJECTTOPATENTFREE) Disodium 2,2'-dithiodiethanesulfonate Bis(2-sulfoethyl)disulfide disodium salt Disodium 2,2`-dithio-bis-ethane sulphonate Disodium 2,2'-disulfanediyldiethanesulfonate 2,2'-Dithiobis(ethanesulfonic acid sodium) salt DIMESNA (DISODIUM 2,2'-DITHIOBISETHANE SULFONATE) 2,2'-dithiobis(ethanesulfonic acid), disodium salt |
CAS | 16208-51-8 |
EINECS | 240-337-2 |
InChI | InChI=1/C4H10O6S4.2Na/c5-13(6,7)3-1-11-12-2-4-14(8,9)10;;/h1-4H2,(H,5,6,7)(H,8,9,10);;/q;2*+1/p-2 |
Molecular Formula | C4H8Na2O6S4 |
Molar Mass | 326.34 |
Melting Point | 273 °C (decomp) |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Appearance | Solid |
Color | White to Off-White |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
Stability | Hygroscopic |
In vitro study | Dimesna dose-dependently regulates paclitaxel-induced MTP multimerization; Mesna, an in vivo metabolite of Dimesna, regulates cisplatin-induced MTP inactivation in a time-dependent manner. Dimesna may prevent or reduce cisplatin-induced nephrotoxicity, possibly through inhibition of adiponectin APN by the Dimesna metabolite mesna disulfide dimer, and may also be associated with glycine groups and/or anionic groups. Cisplatin causes nephrotoxicity through the pathways of nephrotoxic glutamyl transpeptidase (GGT), adiponectin (ANP) and cysteine-coupled-β-lyase (CCBL). Dimesna protects the kidney by coordinating and/or coordinating two main mechanisms to prevent or reduce cisplatin-induced nephrotoxicity. Mesna and its dimer, Dimesna, may be administered concomitantly to reduce toxicity induced by ifosfamide or cisplatin. In the kidney, Dimesna is selectively metabolized to mesna, which exerts a protective effect. In vitro screening of uptake/efflux transporters revealed renal specific uptake of Dimesna by the renal anion transporters OAT 1,OAT 3, and oat4. The saturation values K M for uptake of Dimesna by OAT 1,OAT 3, and OAT4 were 636±280,390±293, and 590±233 μm, respectively. |
In vivo study | Dimesna treatment reduced cyclophosphamide (CP) in rat bladder cancer in a dose-dependent manner. |
biological activity | Dimesna (BNP-7787) is a uroprotective agent that can be used in combination with cancer chemotherapy drugs to reduce urinary toxicity. |
in vitro study | Dimesna dose-dependent regulation of paclitaxel-induced MTP polymerization; meisner, a Dimesna metabolite in vivo, regulates cisplatin-induced MTP inactivation, and the regulatory effect is time-dependent. Dimesna can prevent or reduce renal toxicity caused by cisplatin, and may inhibit adiponectin APN by Dimesna metabolizing meisner disulfide dimer, and may also be related to glycine group and/or anion group. Cisplatin causes nephrotoxicity through pathways such as nephrotoxic glutamyl transpeptidase (GGT), adiponectin (ANP) and cysteine-coupled-β-lyase (CCBL). Dimesna prevent or reduce cisplatin-induced nephrotoxicity by coordinating and/or coordinating the two main mechanisms to protect the kidney. Meisner and its dimers, Dimesna, can be taken simultaneously to reduce the toxicity induced by ifosfamide or cisplatin. In the kidney, Dimesna selective metabolism is meisner, which plays a protective role. In vitro screening of uptake/efflux transport factors revealed renal-specific uptake Dimesna of renal anion transport factors OAT 1,OAT 3, and OAT4. The saturation values K M of OAT 1,OAT 3 and OAT4 uptake Dimesna were 636±280,390 293 and 590±233 μM respectively. |
In vivo studies | Dimesna treatment can reduce cyclophosphamide (CP) in rat bladder cancer, and the inhibitory effect is dose-dependent. |
EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |